The Company is in a positive momentum since mangement changes took place.Revenues will go up and some new developments will be found to be promising... Today we know that we were not told the truth about the time and difficulties that will take place before we see this company getting back to its historic prices but we will be there...
This what I found in the Annual report:
"We entered into the Brazil Agreement with Fiocruz in June 2013, which became effective in January 2014. The technology transfer is designed to be
completed in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own
manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of taliglucerase alfa. The initial term of the
technology transfer is seven years. Under the agreement, Fiocruz committed to purchase at least approximately $40 million worth of taliglucerase alfa during
the first two years of the term. Since the agreement went into effect, we have recorded revenues of approximately $3.5 million for sales of taliglucerase alfa to
Fiocruz in 2014 and, during the first quarter of 2015, we received a purchase order for approximately $5.7 million of taliglucerase alfa out of which we have
delivered approximately $1.7 million of the product. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of
taliglucerase alfa per year"
Elelyso is being prescribed to approximately 30% of newly diagnosed patients and to approximately 25% of all switch patients - is the statement in the annual report, but the agreement is profitable already so the sales should directly affects the profits and as profits are very low, so i recon the sales are low too. Where is 30% of all US newly diagnosed patients sales???
pfizer does the selling and marketing, it's a profit agreement with protalix with no details available, so in the first few years one can assume little or no benefit to protalix.
Is PRKI the real deal below 50 cents? Major pressure on for the stock to climb as new developments sends growth potential soaring.
"In the United States, Elelyso is being prescribed to approximately 30% of newly diagnosed patients and to approximately 25% of all switch patients; however, the total number of patient switches is relatively low" - who can exlain this statement in the lights of the sales results?